Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and ...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...

We recently published a list of Billionaire Steve Cohen’s Top 15 Stock Picks. In this article, we are going to take a look at ...

Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy.

GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results.

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

The latest trading day saw Gilead Sciences (GILD) settling at $92.96, representing a +1.22% change from its previous close.

Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...

Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January ...

UNAIDS urges speed and compassion urging pharmaceutical companies to enable access to new, life-saving medicines ...

Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...